Posttransplant lymphoproliferative disorders (PTLD) are a potentially life-threatening complication of immunosuppression in transplant recipients. The majority of cases are Epstein-Barr virus-associated lesions of B cell origin. T cell PTLD is rare, particularly in pediatric patients. We present an unusual case of monomorphic T cell PTLD with features of angioimmunoblastic T cell lymphoma in an 8-year-old heart transplant patient, presenting with cranial nerve palsy.

Swerdlow SH, International Agency for Research on Cancer, World Health Organization: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, International Agency for Research on Cancer, 2008.
Blaes AH, Morrison VA: Post-transplant lymphoproliferative disorders following solid-organ transplantation. Expert Rev Hematol 2010;3:35-44.
Tsao L, Hsi ED: The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 2007;131:1209-1218.
Morovic A, Jaffe ES, Raffeld M, Schrager JA: Metachronous EBV-associated B-cell and T-cell posttransplant lymphoproliferative disorders in a heart transplant recipient. Am J Surg Pathol 2009;33:149-154.
Lundell R, Elenitoba-Johnson KS, Lim MS: T-cell posttransplant lymphoproliferative disorder occurring in a pediatric solid-organ transplant patient. Am J Surg Pathol 2004;28:967-973.
Draoua HY, Tsao L, Mancini DM, Addonizio LJ, Bhagat G, Alobeid B: T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience. Br J Haematol 2004;127:429-432.
Yang F, Li Y, Braylan R, Hunger SP, Yang LJ: Pediatric T-cell post-transplant lymphoproliferative disorder after solid organ transplantation. Pediatr Blood Cancer 2008;50:415-418.
Williams KM, Higman MA, Chen AR, Schwartz CL, Wharam M, Colombani P, Arceci RJ: Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. Pediatr Blood Cancer 2008;50:667-670.
Webber SA, Naftel DC, Fricker FJ, Olesnevich P, Blume ED, Addonizio L, Kirklin JK, Canter CE: Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet 2006;367:233-239.
Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED, Durnam DM: Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988;72:520-529.
Miyazaki K, Masuya M, Yamaguchi M, Isaka S, Nakase K, Kobayashi T, Nakamura S, Shiku H: Angioimmunoblastic T-cell lymphoma occurring four months after autologous peripheral blood stem cell transplantation with high-dose chemotherapy for follicular lymphoma. Rinsho Ketsueki 2005;46:1065-1070.
de Leval L, Gisselbrecht C, Gaulard P: Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 2010;148:673-689.
Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H, Du MQ, Isaacson PG, Dogan A: Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 2002;99:627-633.
Iannitto E, Ferreri AJ, Minardi V, Tripodo C, Kreipe HH: Angioimmunoblastic T-cell lymphoma. Crit Rev Oncol Hematol 2008;68:264-271.
Attygalle AD, Kyriakou C, Dupuis J, Grogg KL, Diss TC, Wotherspoon AC, Chuang SS, Cabecadas J, Isaacson PG, Du MQ, Gaulard P, Dogan A: Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol 2007;31:1077-1088.
Warnke RA, Jones D, Hsi ED: Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics. Am J Clin Pathol 2007;127:511-527.
Baseggio L, Berger F, Morel D, Delfau-Larue MH, Goedert G, Salles G, Magaud JP, Felman P: Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma. Leukemia 2006;20:296-303.
Diaz-Alderete A, Menarguez J, Alvarez-Doval A, Sabin P, Escudero A, Fernandez-Cruz E, Gil J: Lymphocyte immunophenotype of circulating angioimmunoblastic T-cell lymphoma cells. Br J Haematol 2006;134:347-348.
Ahsanuddin AN, Brynes RK, Li S: Peripheral blood polyclonal plasmacytosis mimicking plasma cell leukemia in patients with angioimmunoblastic T-cell lymphoma: report of 3 cases and review of the literature. Int J Clin Exp Pathol 2011;4:416-420.
Grogg KL, Morice WG, Macon WR: Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. Br J Haematol 2007;137:416-422.
Howarth CB, Bird CC: Immunoblastic sarcoma arising in child with immunoblastic lymphadenopathy. Lancet 1976;2:747-748.
Fiorillo A, Pettinato G, Raia V, Migliorati R, Angrisani P, Buffolano W: Angioimmunoblastic lymphadenopathy with dysproteinemia: report of the first case in childhood evolving toward spontaneous remission. Cancer 1981;48:1611-1614.
de Terlizzi M, Toma MG, Santostasi T, Colella R, Ceci A, De Benedictis G: Angioimmunoblastic lymphadenopathy with dysproteinemia: report of a case in infancy with review of literature. Pediatr Hematol Oncol 1989;6:37-44.
Lee Y, Lee KW, Kim JH, Bang SM, Lee JS, Park BB, Kim WS, Suh C, Kang JH, Ryoo BY, Lee JH, Shin DB: Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma. Korean J Intern Med 2008;23:30-36.
Kobayashi R, Yamato K, Tanaka F, Takashima Y, Inada H, Kikuchi A, Kumagai MA, Sunami S, Nakagawa A, Fukano R, Fujita N, Mitsui T, Tsurusawa M, Mori T: Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan. Pediatr Blood Cancer 2010;54:212-215.
Horneff G, Althaus C, Engelbrecht V, Wahn V: CNS complications in a girl with angioimmunoblastic lymphadenopathy with dysproteinemia (AILD). Neuropediatrics 1996;27:219-222.
Lachenal F, Berger F, Ghesquieres H, Biron P, Hot A, Callet-Bauchu E, Chassagne C, Coiffier B, Durieu I, Rousset H, Salles G: Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients. Medicine (Baltimore) 2007;86:282-292.
Ferrer I, Vidaller A, Fernandez de Sevilla A, Martinez-Matos JA, Montero J, Romagosa V: Peripheral neuropathy associated with angioimmunoblastic lymphadenopathy. Clin Neurol Neurosurg 1988;90:159-162.
Sonobe M, Yasuda H, Okabe H, Terada M, Maeda K, Kawabata T, Kikkawa R: Neuropathy associated with angioimmunoblastic lymphadenopathy-like T-cell lymphoma. Intern Med 1998;37:631-634.
Yamamoto H, Miwa H, Kato Y, Nakamura S, Hara K, Nitta M: Angioimmunoblastic T cell lymphoma with an unusual proliferation of Epstein-Barr virus-associated large B cells arising in a patient with progressive systemic sclerosis. Acta Haematol 2005;114:108-112.
Offit K, Macris NT: Arsenic-associated angioimmunoblastic lymphadenopathy. Lancet 1985;1:220.
Pay S, Dinc A, Simsek I, Can C, Erdem H: Sulfasalazine-induced angioimmunoblastic lymphadenopathy developing in a patient with juvenile chronic arthritis. Rheumatol Int 2000;20:25-27.
Ozoran K, Turgay M, Kinikli G, Duman M, Tolunay O, Tokgoz G: Angioimmunoblastic lymphadenopathy with disproteinemia arising in a patient with rheumatoid arthritis. Scand J Rheumatol 1995;24:58-60.
Hatanaka K, Nakamura N, Kojima M, Ando K, Irie S, Bunno M, Nakamine H, Uekusa T: Methotrexate-associated lymphoproliferative disorders mimicking angioimmunoblastic T-cell lymphoma. Pathol Res Pract 2010;206:9-13.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.